Menu

  • Electrophysiology
  • Therapies & Procedures
  • Patient Care Portfolio
  • Reimbursement
  • Education & Training

    • Empower your diagnostic expertise through unmatched precision and AI trained on the world’s largest real-world ICM patient database.1–8

    Unmatched precision1–4

    Accurate diagnosis for efficient treatment1–4,8

    The world’s
    most accurate ICM1–4

    98.9%

    AF duration sensitivity4,8

    Most clinically
    studied ICM, with

    1,100+

    published clinical articles and abstracts9

    ECG clarity without compromise

    Visualize data your way.

    • High-resolution ECG waveforms
    • Sweep speed control
    • Navigation control and multiple views
    • Amplitude zoom
    • Adjustable calipers and annotations

    AI advantage

    There is a difference between AI and AI you can trust.5–8

    • Developed by the industry leader in cardiac rhythm and diagnostic tools5,8
    • Trained on the world’s largest real-world ICM patient database4–8,10
    • Reduced false alerts by 91%, lowest nonactionable alerts on the market1–4,6,8

    Recent clinical evidence highlights

    Observations from the ALLEVIATE-HF Clinical Trial published in JACC

    From insight to intervention: Arrhythmia observations in symptomatic heart failure patients11

    Read manuscript (open in new window)
    Download summary (open in new window)

    Analyses design

    Prospective intervention study, randomized for heart failure congestion management, in 52 U.S. sites

    Analyses findings

    Continuous monitoring with Reveal LINQ™ ICM revealed that many heart failure patients are at high risk of arrhythmia leading to therapeutic interventions.

    77%

    of patients with one or more arrhythmias detected

    12%

    of patients with VT/VF

    65%

    of patients with AF

    23%

    of patients with newly diagnosed AF

    42%

    of patients with bradycardia/Pause

    Patient impact

    Arrhythmias detected by Reveal LINQ™ ICM in this heart failure patient cohort were associated with a higher likelihood of therapeutic intervention following arrhythmia diagnosis.

    1 in 4

    (23%) patients received a CIED within 36 months.

    1 in 4

    (26%) patients received an ablation within 36 months.

    1 in 4

    (29%) patients with no OAC at baseline had OAC initiation within 36 months.

    45%

    of patients had at least one clinical action taken after ICM-detected arrhythmia.

    Related products